{"organizations": [], "uuid": "188731f7283ff2dce41d15e6159c5e00c399d593", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-adma-biologics-reports-fy17-financ/brief-adma-biologics-reports-fy17-financial-results-idUSASB0C8PT", "country": "US", "domain_rank": 408, "title": "BRIEF-Adma Biologics Reports FY'17 Financial Results", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.836, "site_type": "news", "published": "2018-03-05T20:12:00.000+02:00", "replies_count": 0, "uuid": "188731f7283ff2dce41d15e6159c5e00c399d593"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-adma-biologics-reports-fy17-financ/brief-adma-biologics-reports-fy17-financial-results-idUSASB0C8PT", "ord_in_thread": 0, "title": "BRIEF-Adma Biologics Reports FY'17 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "adma biologics inc", "sentiment": "negative"}, {"name": "adma", "sentiment": "none"}, {"name": "adma biologics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Adma Biologics Inc:\n* ADMA BIOLOGICS REPORTS FULL YEAR 2017 FINANCIAL RESULTS * ADMA BIOLOGICS - ‍BELIEVE PROGRESS MADE WITH COMPLIANCE ENHANCEMENT PROGRAM ALLOWED REMEDY OF IDENTIFIED COMPLIANCE ISSUES AT BOCA FACILITY​\n* ADMA BIOLOGICS - ‍BELIEVE CO NOW READY FOR ROUTINE INSPECTION OF BOCA FACILITY BY U.S. FDA\n* ADMA BIOLOGICS - ‍AT DEC 31, 2017, HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS OF $43.1 MILLION, VERSUS $15.3 MILLION AT DEC 31, 2016​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T20:12:00.000+02:00", "crawled": "2018-03-06T22:35:21.000+02:00", "highlightTitle": ""}